Resource Summary Report

Generated by RRID on Sep 2, 2026

SU-DIPG-IV

RRID:CVCL_IT39
Type: Cell Line

Proper Citation

RRID:CVCL_IT39

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_IT39

Proper Citation: RRID:CVCL_IT39

Description: Cell line SU-DIPG-IV is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Diffuse intrinsic pontine glioma

Defining Citation: PMID:25366336, PMID:25939062, PMID:28823557, PMID:31439867, PMID:33319914, PMID:34078608, PMID:34215733

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SU-DIPG-IV

Synonyms: SUDIPGIV, SU-DIPG-4, SUDIPG4, DIPG IV, DIPGIV, DIPG 4, DIPG-4, DIPG4, SJHGG054832, Stanford University-Diffuse Intrinsic Pontine Glioma-IV

Cross References: BTO:BTO_0005955, cancercelllines:CVCL_IT39, GEO:GSM4969586, GEO:GSM4969587, GEO:GSM4969588, GEO:GSM4969589, GEO:GSM4969615, GEO:GSM4969637, GEO:GSM4969638, GEO:GSM4969639, Wikidata:Q54970734

ID: CVCL_IT39

Record Creation Time: 20220427T221612+0000

Record Last Update: 20260830T000034+0000

Ratings and Alerts

No rating or validation information has been found for SU-DIPG-IV.

No alerts have been found for SU-DIPG-IV.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Umaru B, et al. (2026) BMI-1 modulation and trafficking during M phase in diffuse intrinsic pontine glioma. FEBS open bio, 16(6), 1213.

Calvo Fern??ndez E, et al. (2026) Systematic design of combination therapy by targeting master regulators of coexisting diffuse midline glioma cell states. Nature genetics, 58(5), 1112.

Venneti S, et al. (2023) Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. Cancer discovery, 13(11), 2370.

Panditharatna E, et al. (2022) BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma. Cancer discovery, 12(12), 2880.

Siddaway R, et al. (2022) Splicing is an alternate oncogenic pathway activation mechanism in glioma. Nature communications, 13(1), 588.

Metselaar DS, et al. (2022) AURKA and PLK1 inhibition selectively and synergistically block cell cycle progression in diffuse midline glioma. iScience, 25(6), 104398.

Tsai JW, et al. (2022) FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits. Cancer research, 82(17), 2980.

Chung C, et al. (2020) Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas. Cancer cell, 38(3), 334.

Fortin J, et al. (2020) Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas. Cancer cell, 37(3), 308.

Anastas JN, et al. (2019) Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG. Cancer cell, 36(5), 528.